ScripArtificial intelligence-enabled drug discovery and development is one of the hottest topics in the biopharmaceutical industry, capturing the imaginations of investors, entrepreneurs and veterans alike
ScripSubgroup data from ProKidney’s Phase II REGEN-007 study of rilparencel in patients with chronic kidney disease (CKD) and type 2 diabetes have encouraged the company to try and use an ongoing Phase III
ScripActithera has raised $75.5m in a series A financing to develop radioligand therapies (RLTs) that use a covalent drug design to prolong their effects on cancer cells. The early-stage company’s lead can
ScripFrontline Indian firms appear keen to accelerate product in-licensing deals with foreign companies and these efforts have now evolved from a “supplementary tactic” to a cornerstone of their strategy,